Cobicistat (Molecule of the Month for May 2017)
Tybost
Cobicistat ) is a licensed drug for use in the treatment of human immunodeficiency virus infection (HIV/AIDS). Its major mechanism of action is through the inhibition of human CYP3A proteins. Cobicistat inhibits liver enzymes that metabolize other medications used to treat HIV, notably elvitegravir, an HIV integrase inhibitor. By combining cobicistat with elvitegravir, higher concentrations of the latter are achieved in the body with lower dosing, theoretically enhancing elvitegravir's viral suppression while diminishing its adverse side-effects.
Cobicistat is a drug analogue of ritonavir, in which the valine moiety is exchanged for a 2-morpholinoethyl group, and the backbone hydroxyl group is removed. These changes effectively eliminate the anti-HIV activity of ritonavir while preserving its inhibitory effects on the CYP3A isozyme family of proteins.
Formal Chemical Name (IUPAC)
thiazol-5-ylmethyl ((2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)ureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-yl)(methyl)carbamate
References
click on the picture of Cobicistat above to interact
with the 3D model of the
Cobicistat structure
(this will open a new browser window)
C40H53N7O5S2
Update by Karl Harrison
(Molecule of the Month for
May 2017
)
All the images on this web site are are made available with a Creative Commons Attribution license and so can be used as long as the attribution © Karl Harrison 3DChem.com is written with the image. High resolution images and illustrations are available on request.